Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells

Journal of Cellular Biochemistry

Volumn 108, Issue 4, 2009, Pages 935-946

  Berges, Carsten ^a   Haberstock, Heinrich ^a   Fuchs, Dominik ^a   Sadeghi, Mahmoud ^a   Opelz, Gerhard ^a   Daniel, Volker ^a   Naujokat, Cord ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bortezomib; Mitochondrial apoptotic pathway; Proteasome; Proteasome inhibition; T cells

Indexed keywords

APOPTOSIS INDUCING FACTOR; BIM PROTEIN; BORTEZOMIB; CASPASE 3; CASPASE 9; CYTOCHROME C; HETERODIMER; PROTEASOME; PROTEIN BAK; PROTEIN BAX; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SERINE PROTEINASE OMI; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; INTRACELLULAR TRANSPORT; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN TRANSPORT; T LYMPHOCYTE ACTIVATION;

APOPTOSIS; BORONIC ACIDS; CASPASE 3; CASPASE 9; CD4-POSITIVE T-LYMPHOCYTES; CYTOCHROMES C; DENDRITIC CELLS; DIMERIZATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MEMBRANE POTENTIALS; MITOCHONDRIA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 70350509121     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22325     Document Type: Article

References (49)

1. Adrain C, Creagh EM, Martin SJ. 2001. Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J 20:6627-6636. (Pubitemid 33134193)
2. Berger AB, Sexton KB, Bogyo M. 2006. Commonly used caspase inhibitors designed based on substrate specificity profiles lack selectivity. Cell Res 16:961-963. (Pubitemid 44973583)
3. Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, Daniel V, Naujokat C. 2008. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 124:234-246. (Pubitemid 351692904)
4. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villarón E, Schenkein D, Pandiella A, San Miguel J. 2006. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107:3575-3583.
5. Chauhan D, Hideshima T, Anderson KC. 2005. Proteasome inhibition in multiple myeloma: Therapeutic implication. Annu Rev Pharmacol Toxicol 45:465-476. (Pubitemid 40261814)
6. Ciechanover A. 2006. The ubiquitin proteolytic system. Neurology 66(Suppl 1):S7-S19.
7. Denault JB, Eckelman BP, Shin H, Pop C, Salvesen GS. 2007. Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9. Biochem J 405:11-19. (Pubitemid 46999920)
8. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH. 1997. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438-441.
9. Drexler HCA. 1997. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94:855-860. (Pubitemid 27074411)
10. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. 2008. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 86:1754-1761.
11. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. 2008a. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 103:270-283.
12. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. 2008b. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem Biophys Res Commun 374:309-314.
13. Glickman MH, Ciechanover A. 2002. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 82:373-428. (Pubitemid 34654457)
14. Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ, Shore GC. 1998. Regulated targeting of Bax to mitochondria. J Cell Biol 143:207-215.
15. Groll M, Huber R. 2004. Inhibitors of the eukaryotic 20S proteasome core particle: A structural approach. Biochim. Biophys Acta 1695:33-44. (Pubitemid 39574966)
16. Henderson CJ, Aleo E, Fontanini A, Maestro R, Paroni G, Brancolini C. 2005. Caspase activation and apoptosis in response to proteasome inhibitors. Cell Death Differ 12:1240-1254. (Pubitemid 41195112)
17. Karst AM, Li G. 2007. BH3-only proteins in tumorigenesis and malignant melanoma. Cell Mol Life Sci 64:318-330. (Pubitemid 46440203)
18. Krammer PH, Arnold R, Lavrik IN. 2007. Life and death in peripheral T cells. Nat Rev Immunol 7:532-542.
19. Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P. 2007. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 14:44-55. (Pubitemid 44911893)
20. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. 2003. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278:18811-18816. (Pubitemid 36799262)
21. Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J. 2001. A proteasome inhibitor prevents mouse heart allograft rejection. Transplantation 72:196-202. (Pubitemid 32729334)
22. Maki CG, Huibregtse M, Howley PM. 1996. In vivo ubiquitination and proteasome-mediated degradadtion of p53. Cancer Res 56:2649-2654.
23. Marchenko ND, Wolff S, Erster S, Becker K, Moll UM. 2007. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 26:923-934. (Pubitemid 46321418)
24. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ, Roy S, Nicholson DW, Vaux DL, Bouillet P, Adams JM, Strasser A. 2002. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 419:634-637.
25. Mattingly LH, Gault RA, Murphy WJ. 2007. Use of systemic proteasome inhibition as an immune-modulating agent in disease. Endocr Metab Immune Disord Drug Targets 7:29-34.
26. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, Chandra J. 2007. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110:267-277. (Pubitemid 47026844)
27. + T cells generate intermediate caspase activity and cleavage of caspase-8 substrates. J Immunol 174:3999-4009.
28. Murahashi H, Azuma H, Zamzami N, Furuya KJ, Ikebuchi K, Yamaguchi M, Yamada Y, Sato N, Fujihara M, Kroemer G, Ikeda H. 2003. Possible contribution of apoptosis-inducing factor (AIF) and reactive oxygen species (ROS) to UVB-induced caspase-independent cell death in the T cell line Jurkat. J Leukoc Biol 73:399-406. (Pubitemid 36790856)
29. Naujokat C, Hoffmann S. 2002. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 82:965-980. (Pubitemid 34894345)
30. Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S, Possinger K. 2000. Proteasome inhibitors induce caspase-dependent apoptosis and accumulation of p21 in human immature leukemic cells. Eur J Haematol 65:221-236. (Pubitemid 30760338)
31. Naujokat C, Berges C, Höh A, Wieczorek H, Fuchs D, Ovens J, Sadeghi M, Opelz G, Daniel V. 2007a. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Immunology 120:20-32. (Pubitemid 44950477)
32. Naujokat C, Fuchs D, Berges C. 2007b. Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition. Biochim Biophys Acta 1773:1389-1397. (Pubitemid 47374847)
33. Nechushtan A, Smith CL, Hsu YT, Youle RJ. 1999. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 18:2330-2341. (Pubitemid 29213267)
34. Nencioni A, Hua F, Dillon CP, Yokoo R, Scheiermann C, Cardone MH, Barbieri E, Roccom I, Garuti A, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A. 2005. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 105:3255-3262. (Pubitemid 40504347)
35. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE. 2008. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14:748-755. (Pubitemid 351951516)
36. Orlowski RZ, Kuhn DJ. 2008. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res 14:1649-1657.
37. Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. 2002. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci USA 99:1259-1263. (Pubitemid 34136480)
38. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. 2006. Cytochrome c release from mitochondria proceeds by a two-step process. Blood 107:257-264.
39. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. 2008. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 8:1-9.
40. Schuler M, Green DR. 2001. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 29:684-688.
41. Sun XM, Bratton SB, Butterworth M, Mac Farlane M, Cohen GM. 2002. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem 277:11345-11351. (Pubitemid 34952900)
42. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ. 2004. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 101:8120-8125. (Pubitemid 38698064)
43. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. 1999. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441-446. (Pubitemid 29078912)
44. Uren RT, Dewson G, Bonzon C, Lithgow T, Newmeyer DD, Kluck RM. 2005. Mitochondrial release of pro-apoptotic proteins: Electrostatic interactions can hold cytochrome c but not Smac/DIABLO to mitochondrial membranes. J Biol Chem 280:2266-2274.
45. Vaux DL, Silke J. 2005. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 6:2872-2897.
46. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. 2001. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292:727-730. (Pubitemid 32385543)
47. Yang QH, Du C. 2004. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLA cells. J Biol Chem 279:16963-16970. (Pubitemid 38560449)
48. Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C. 2003. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev 17:1487-1496. (Pubitemid 36734706)
49. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. 2003. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl + cells sensitive and resistant to STI571. Blood 102:3765-3774. (Pubitemid 37409399)